サンプル依頼リスト カート
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：網膜医薬品の世界市場（2023年）：2022年～2028年の分析
市場調査レポート
商品コード
1336819

網膜医薬品の世界市場（2023年）：2022年～2028年の分析

2023 Retinal Pharmaceuticals Market Report: Global Analysis for 2022 to 2028
出版日: | 発行: Market Scope, LLC | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
網膜医薬品の世界市場（2023年）：2022年～2028年の分析
出版日: 2023年08月31日
発行: Market Scope, LLC
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の網膜医薬品市場について調査し、市場の概要とともに、今後5年間の市場パフォーマンス予測、重要な将来動向、および市場に参入する企業29社の企業プロファイルなどを提供しています。

目次

  • 網膜疾患とその危険因子に関する考察
  • これらの疾患の診断と治療
  • 網膜医療と網膜専門医の世界な見解
  • 市場における網膜用医薬品と生物製剤
  • 開発パイプラインにある治験薬
  • 網膜医薬品を開発・販売している企業のプロファイルと、前臨床プログラムを有する追加企業のリスト
目次

What's New:

The "2023 Retinal Pharmaceuticals Market Report" features new sales and disease prevalence forecasts through 2028. The report now covers adoption plans for complement inhibitors and new anti-VEGFs by ophthalmologists in the United States and Western Europe, as well as treatment patterns for anti-VEGFs. In addition, it includes IVT injection shares by drug in the United States and Western Europe.

The new report also evaluates more development-stage categories, therapies, and companies.

The "2023 Retinal Pharmaceuticals Market Report" analyzes the market for the treatment of retinal diseases and discusses important trends and key factors for future market success. It examines the market's evolution and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 29 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

The report explores a variety of topics intended to provide depth and context to the understanding of market dynamics in this ophthalmic segment. Our coverage includes:

  • Discussions of retinal diseases and their risk factors.
  • Diagnosis and treatment of these diseases.
  • A global view of retinal care and retina specialists.
  • Retinal pharmaceuticals and biologics in the marketplace.
  • Investigational agents in the development pipeline.
  • Profiles of companies developing and marketing retinal pharmaceuticals, plus a listing of additional companies with preclinical programs.

The report provides market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, biosimilars, complement inhibitors expected to enter the marketplace within five years, gene therapies, and others. The report also includes a separate forecast for sustained-drug-delivery devices in retina.

The report delves into the development pipelines of 11 categories of retinal pharmaceuticals:

  • VEGF inhibitors
  • Other vascular growth factor inhibitors
  • Complement inhibitors
  • Neuroprotectors
  • Mitochondrial protectors
  • Visual cycle modulators
  • Plasma kallikrein inhibitors
  • Gene therapies
  • Stem cell therapies
  • Anti-inflammatories
  • Other mechanisms of action

Author Profile:

Peter Downs

Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International.

Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets for organ and tissue transplantation. Since joining Market Scope, he has traveled to several markets outside the US, including China, Europe, and India, to study ophthalmology at the local level.

In addition to his research and writing efforts on the ophthalmic market, he is also a contributor to Ophthalmic Market Perspectives, the firm's monthly industry newsletter.